CMS Policy Reversal Strengthens Celularity's Market Position in Skin Substitute Segment

Celularity Inc. (CELU) receives favorable news regarding its Biovance and Biovance 3L products following the Centers for Medicare & Medicaid Services’ decision to withdraw previously established Local Coverage Determinations (LCDs) for skin substitute grafts and cellular tissue-based products. This policy reversal, effective January 1, 2026, represents a significant shift in the regulatory landscape for diabetic foot ulcer and venous leg ulcer treatments.

Policy Reversal: From Restriction to Standardization

The CMS initially introduced LCDs in late December 2024 as part of the Medicare 2026 Skin Substitute Update, establishing coverage criteria that effectively eliminated reimbursement eligibility for 158 competing products. However, the agency announced the withdrawal of these determinations on December 24, 2025, fundamentally altering the market dynamics. Rather than creating product-specific restrictions, CMS has implemented a standardized payment framework that applies uniformly across all skin substitute applications in clinical settings.

Unified Payment Structure and Financial Implications

Under the new regulatory environment, Medicare will establish a flat-rate reimbursement of $127.28 per square centimeter for all skin substitute procedures in physician offices and hospital outpatient facilities. This standardized approach eliminates the previous discriminatory framework that favored certain products while excluding others from coverage. Celularity’s leadership expressed confidence that both Biovance formulations can operate sustainably under this payment structure, suggesting the company’s cost efficiency aligns favorably with the revised reimbursement model.

Manufacturing Excellence as Competitive Advantage

Dr. Robert Hariri, CEO and Chairman, emphasized the company’s operational strengths, particularly its GMP/GTP-certified manufacturing facility in New Jersey. The facility utilizes advanced Industry 5.0 manufacturing systems incorporating digitalization and artificial intelligence to optimize production efficiency and supply chain resilience. This technological infrastructure positions Celularity to capitalize on the policy reversal by ensuring reliable product availability and scalability in a competitive market without the previous coverage restrictions.

Market Performance

CELU shares demonstrated resilience throughout the annual trading cycle, fluctuating between $1.00 and $4.35. On Friday, the stock closed at $1.34, reflecting a 1.52% daily gain following the policy announcement.